Medico Remedies Falls 3.91%: Death Cross and Downgrade Signal Bearish Momentum

1 hour ago

Share Via

Medico Remedies Ltd experienced a challenging week from 16 to 20 March 2026, with its stock price declining 3.91% to close at Rs.38.07, underperforming the Sensex which fell 0.28% over the same period. The week was marked by significant technical developments, including the formation of a Death Cross and a downgrade to a 'Sell' rating by MarketsMojo, reflecting growing bearish momentum despite the company’s solid financial performance.

Key Events This Week

16 Mar: Stock opens at Rs.39.18, down 1.11% amid Sensex gains

18 Mar: Death Cross formation signals potential bearish trend

19 Mar: Downgrade to 'Sell' rating amid technical weakness

20 Mar: Slight recovery to Rs.38.07, but weekly loss persists

Week Open

Rs.39.62

Week Close

Rs.38.07

-3.91%

Week Low

Rs.37.80

Sensex Change

-0.28%

16 March 2026: Weak Start Amid Broader Market Gains

Medico Remedies began the week at Rs.39.18, down 1.11% from the previous Friday’s close of Rs.39.62. This decline contrasted with the Sensex’s 0.47% gain to 33,673.11, indicating early weakness in the stock despite positive market sentiment. Trading volume was moderate at 7,607 shares, suggesting cautious investor participation.

17 March 2026: Continued Decline on Thin Volume

The downward trend persisted with the stock slipping 1.20% to Rs.38.71, while the Sensex advanced 0.79% to 33,940.18. Notably, volume dropped sharply to 1,408 shares, reflecting limited trading interest. The divergence between the stock’s performance and the broader market hinted at growing investor concern.

18 March 2026: Death Cross Formation Signals Bearish Outlook

On 18 March, Medico Remedies formed a Death Cross, a significant technical indicator where the 50-day moving average crossed below the 200-day moving average. This event is widely regarded as a bearish signal, often preceding extended downtrends. The stock closed at Rs.38.55, down 0.41%, while the Sensex surged 1.15% to 34,329.13. The technical deterioration underscored the stock’s weakening momentum amid a strong market backdrop.

19 March 2026: Downgrade to 'Sell' Amid Technical Weakness

MarketsMOJO downgraded Medico Remedies from 'Hold' to 'Sell' on 19 March, citing deteriorating technical indicators and prolonged underperformance. The stock fell 1.95% to Rs.37.80, sharply underperforming the Sensex which plunged 3.13% to 33,255.16. Despite the negative price action, the company reported strong financial metrics including a 30.46% PAT growth over six months and a robust ROCE of 20.65%. However, the technical outlook dominated sentiment, prompting the rating revision.

20 March 2026: Minor Recovery Fails to Offset Weekly Losses

Medico Remedies closed the week at Rs.38.07, gaining 0.71% on the day with volume rising to 3,792 shares. The Sensex also recovered 0.51% to 33,423.61. Despite this modest rebound, the stock ended the week down 3.91%, significantly underperforming the Sensex’s 0.28% decline. The week’s events reinforced a cautious outlook amid persistent technical challenges.

Date	Stock Price	Day Change	Sensex	Day Change
2026-03-16	Rs.39.18	-1.11%	33,673.11	+0.47%
2026-03-17	Rs.38.71	-1.20%	33,940.18	+0.79%
2026-03-18	Rs.38.55	-0.41%	34,329.13	+1.15%
2026-03-19	Rs.37.80	-1.95%	33,255.16	-3.13%
2026-03-20	Rs.38.07	+0.71%	33,423.61	+0.51%

Key Takeaways from the Week

Bearish Technical Signals: The formation of the Death Cross on 18 March marked a pivotal bearish technical development, signalling a shift in momentum that was confirmed by subsequent indicators such as MACD, RSI, and Bollinger Bands. This technical deterioration culminated in a downgrade to a 'Sell' rating, reflecting heightened caution among analysts.

Underperformance vs Sensex: Medico Remedies declined 3.91% over the week, significantly underperforming the Sensex’s 0.28% fall. This divergence highlights the stock’s vulnerability amid broader market fluctuations and technical weakness.

Strong Financial Fundamentals: Despite the negative price action, the company demonstrated robust operational metrics, including a 30.46% PAT growth over six months, a 20.65% ROCE, and prudent debt management. These fundamentals suggest resilience in business performance despite market headwinds.

Micro-Cap Volatility: The stock’s micro-cap status contributes to elevated price volatility and liquidity risk, factors that may exacerbate downward moves during periods of technical weakness.

Conclusion: A Week Marked by Technical Setbacks Amid Solid Fundamentals

Medico Remedies Ltd’s week was dominated by technical challenges that overshadowed its strong financial performance. The Death Cross formation and subsequent downgrade to a 'Sell' rating by MarketsMOJO underscore a bearish momentum that has led to significant underperformance relative to the Sensex. While the company’s operational metrics remain robust, the prevailing technical weakness and micro-cap volatility suggest a cautious near-term outlook. Investors should carefully weigh these factors within their portfolio strategies, recognising the complex interplay between fundamental strength and market sentiment.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →

{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)

MOJO SCORE